A lot depends on what "in between" actually means.
I think almost no one would be willing to return, say, to the early 1900s when it comes to medical science and available treatment options.
Things like anti-retroviral therapy and CAR-T are just too nice to have when something otherwise fatal hits you. But that requires top-notch chemistry and biology, which requires top-notch lab equipment and computers, which requires top-notch material science and industry etc.
I am not sure if you can sustain all of this if all the the relevant PhDs work 16 hour workweeks. I am also not sure which parts of the modern economy can be left out to regress to a previous stage of development if you still want to retain the capability to treat cancer with advanced biologicals. The supply chains are just too complex.
Maybe in the age of AI and robots the options are different, but not before.